Tolerability and safety with aducanumab in Alzheimer's disease in a community-based setting on a slower titration schedule

被引：1
|
作者：
Devi, Gayatri [1 ]
机构：
[1] Pk Ave Neurol Zucker Sch Med, New York, NY USA
来源：
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY | 2023年 / 71卷 / 02期
关键词：
D O I：
10.1111/jgs.18059
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
引用
收藏
页码：671 / 672
页数：2
相关论文
共 50 条
  • [41] The utility of apolipoprotein E genotyping in the diagnosis of Alzheimer's disease in a community-based case series
    Tsuang, D
    Larson, EB
    Bowen, J
    McCormick, M
    Teri, L
    Nochlin, D
    Leverenz, J
    Peskind, ER
    Lim, A
    Raskind, M
    Thompson, ML
    Mirra, S
    Gearing, M
    Schellenberg, G
    Kukull, W
    BIOLOGICAL PSYCHIATRY, 1999, 45 (08) : 138S - 138S
  • [42] Safety & tolerability of slow titration of rivastigmine (Exelon) in the treatment of patients with Alzheimer's Disease (AD): An overall analysis of two prospective studies.
    Shua-Haim, JR
    Smith, JM
    Amin, S
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2001, 49 (04) : S76 - S77
  • [43] Exploring and Evaluating Patient Safety Culture in a Community-Based Primary Care Setting
    Desmedt, Melissa
    Bergs, Jochen
    Willaert, Benjamin
    Schrooten, Ward
    Vlayen, Annemie
    Hellings, Johan
    Claes, Neree
    Vandijck, Dominique
    JOURNAL OF PATIENT SAFETY, 2021, 17 (08) : E1216 - E1222
  • [44] Serum cholesterol and risk of Alzheimer disease - A community-based cohort study
    Li, G
    Shofer, JB
    Kukull, WA
    Peskind, ER
    Tsuang, DW
    Breitner, JCS
    McCormick, W
    Bowen, JD
    Teri, L
    Schellenberg, GD
    Larson, EB
    NEUROLOGY, 2005, 65 (07) : 1045 - 1050
  • [45] Memantine for the treatment of Alzheimer's disease: Tolerability and safety data from clinical trials
    Farlow M.R.
    Graham S.M.
    Alva G.
    Drug Safety, 2008, 31 (7) : 577 - 585
  • [46] Safety tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease
    Sramek, JJ
    Anand, R
    Wardle, TS
    Irwin, P
    Hartman, RD
    Cutler, NR
    LIFE SCIENCES, 1996, 58 (15) : 1201 - 1207
  • [47] An investigation into the safety, tolerability, and efficacy of high dose rivastigmine treatment in Alzheimer's disease
    Shua-Haim, JR
    Pass, MD
    Patel, S
    Lee, P
    Patel, P
    NEUROBIOLOGY OF AGING, 2004, 25 : S196 - S196
  • [48] Investigational γ-secretase inhibitor in Phase II tolerability and safety study for Alzheimer's disease
    不详
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2011, 11 (09) : 1226 - 1226
  • [49] Safety and tolerability of rivastigmine capsules plus memantine in patients with probable Alzheimer's disease
    Brannan, Stephen
    Koumaras, Barbara
    Figiel, Gary
    Farlow, Martin
    ANNALS OF NEUROLOGY, 2008, 64 : S40 - S41
  • [50] Efficacy and long-term safety and tolerability of rosiglitazone XR in Alzheimer's disease
    Zvartau-Hind, M.
    Rainer, M.
    Hosford, D.
    Ormandy, G.
    Altman, J.
    Saunders, A. M.
    Blesa, R.
    Tsolaki, M.
    Gold, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 : 57 - 58
12345